The purpose of the study is to explore how this imaging method can be used to detect changes in the brain that are associated with neurodegenerative diseases. Participants will receive injections of the solution and undergo imaging scans to map the presence of tau, a protein that can build up in the brain and is linked to these diseases. The study will also involve some participants receiving a placebo, which is a substance with no active treatment, to compare results.

Throughout the study, participants will have regular imaging sessions and may undergo additional tests to measure various substances in the body, such as proteins in the blood and cerebrospinal fluid. These tests help researchers understand how the disease progresses and how the treatment affects the brain. The study aims to provide valuable insights into the early detection and understanding of neurodegenerative diseases, potentially leading to better treatment options in the future.

The purpose of the study is to determine whether ALKS 2680 can reduce daytime sleepiness in adults with Narcolepsy Type 1. Participants will be randomly assigned to receive either the study drug or a placebo for about twelve weeks. During the study, they will complete a questionnaire called the Epworth Sleepiness Scale that asks how likely they are to fall asleep in everyday situations, and they will take a short test called the Maintenance of Wakefulness Test that measures how long they can stay awake when asked to do so. Their episodes of cataplexy will also be recorded each week.

Throughout the trial, researchers will monitor participants for any side effects and will collect the questionnaire and test results to evaluate the safety and effectiveness of the medication. The collected information will help decide if the drug provides a beneficial option for managing the symptoms of this sleep disorder.

Participants will receive the study drug in a three‑step dose‑increase schedule, with each dose taken for several weeks. During the study, doctors will check vital signs, perform blood tests, and record heart rhythm using a simple test called a ECG. Researchers will also examine how the body absorbs and clears the medication (pharmacokinetics) and how the medication works in the body (pharmacodynamics). Throughout the trial, participants will keep a diary of their seizure events and complete questionnaires about their quality of life. After the initial phase, individuals may choose to continue in an optional open‑label extension where they can keep receiving the medication.

The purpose of the study is to see whether votoplam can slow the progression of Huntington’s Disease. Participants will be randomly assigned to receive either the study drug or the placebo, and neither the participants nor the researchers will know which one is given. The study lasts about three years, with regular visits to check health, perform simple tests, and collect blood samples.

During the visits, doctors will use a questionnaire called the Unified Huntington’s Disease Rating Scale to track changes in movement, thinking and daily abilities. Blood will be checked for a protein called mutant huntingtin (a faulty version of a normal brain protein), and safety will be monitored by recording any side effects. The information collected will help understand if the drug is safe and helpful.

The purpose of the study is to evaluate the safety and tolerability of the drug, meaning how well participants can use it without harmful side effects. Participants will be assigned by chance to receive either the study drug or the placebo, and neither the participants nor the study staff will know which treatment is given (a double‑blind design). The trial will last several weeks, during which participants will take one tablet each day and attend regular visits for health checks and questionnaires about sleepiness and cataplexy.

Throughout the study, researchers will monitor any side effects and record changes in daytime sleepiness and the frequency of cataplexy episodes. The information collected will help determine whether the medication is safe enough to move forward in development for people with this disorder.

After a stroke is diagnosed, eligible individuals receive a single infusion of the assigned treatment shortly after the event. They remain in the hospital for a few days for close monitoring of any side effects and for basic health checks. Follow‑up visits are scheduled over the next three months to track recovery, including assessments of neurological function and overall health. The study collects information on any serious bleeding events, other adverse reactions, and measures of disability and functional outcome during this period.

The purpose of the study is to determine whether the medication can lower the frequency of nocturnal attacks in people with chronic Cluster headache. Participants will be randomly assigned to receive either the active medication or a matching placebo, and neither the participants nor the study staff will know which one is given. The medication will be taken twice each night for about four weeks, with regular visits to check health status and record headache occurrences.

Throughout the trial, safety will be monitored by measuring vital signs such as blood pressure, checking weight, and asking participants to complete simple questionnaires about mood, sleep quality, and overall well‑being. Any side effects, also called adverse events, will be recorded, and participants will keep a diary of their headaches and any rescue medicines they use, such as oxygen or triptans.

The purpose of the study is to find the optimal dose of E2086 for reducing excessive daytime sleepiness in adults with narcolepsy. Participants are randomly assigned to receive either the active tablet or placebo for several weeks. Sleepiness is measured by the time it takes to fall asleep during a series of four MWT (maintenance of wakefulness tests), reported as MSL (mean sleep latency), and by a questionnaire called the ESS that asks about the chance of dozing in everyday situations. Safety monitoring includes blood pressure checks with a device that measures pressure over 24 hours (ABPM), heart rhythm recording with a 12‑lead ECG, laboratory blood tests, and a brief interview to assess suicidal thoughts using the C‑SSRS (Columbia‑Suicide Severity Rating Scale). The study includes people with both type 1 (NT1) and type 2 (NT2) forms of narcolepsy and lasts about four weeks, with regular clinic visits for assessments.

The purpose of the study is to determine whether the medication can prevent or lessen further disability in people with these disease forms. Participants will take the tablet each day for about 12 months and will visit the clinic at the start, midway, and at the end to check safety and to measure walking ability using a simple 25‑foot walk test called the T25FW. No other experimental treatment will be given.

During the year, participants will keep a short diary of any new symptoms or side effects and will have routine blood checks to monitor health. The final visit will include the same walking test and a review of overall condition. The study is open‑label, meaning the medication being taken is known to both the doctors and the participants.